India, June 2 -- Shares of Instil Bio, Inc. (TIL) were surging around 49 percent in the pre-market activity on the Nasdaq after the clinical-stage biopharmaceutical company announced Monday the appointment of Jamie Freedman as Chief Medical Officer.
The company expects Freedman, with extensive experience and leadership in biopharmaceutical R&D, to be a tremendous asset in advancing AXN-2510, a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers.
Freedman, a Hematologist-Oncologist, said, "AXN-2510 has the potential to redefine the standard of care for solid tumors. Our opportunity to accelerate the development of this promising PD-L1xVEGF bispecific is unique, and Im exc...